"RIV/00064173:_____/11:#0000382" . "Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma" . "1"^^ . "Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MM treated with thalidomide-based (T) regimens (n = 105) or bortezomib-based (B) regimens (n = 106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTP from the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p = 0.774), TTP (p = 0.207), or OS (p = 0.889) were observed between the two groups. In conclusion, T- and B-based regimens appear to be equally effective in the treatment of first MM relapse." . . . . . "Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma"@en . . "RIV/00064173:_____/11:#0000382!RIV14-MZ0-00064173" . "[E3AF6515F563]" . "229271" . . . . "12" . "Gregora, Ev\u017Een" . "90" . . . . "7"^^ . "Annals of Hematology" . . "0939-5555" . "I, N, V" . "Multiple myeloma; thalidomide"@en . "10.1007/s00277-011-1206-3" . "000296730700008" . "Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MM treated with thalidomide-based (T) regimens (n = 105) or bortezomib-based (B) regimens (n = 106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTP from the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p = 0.774), TTP (p = 0.207), or OS (p = 0.889) were observed between the two groups. In conclusion, T- and B-based regimens appear to be equally effective in the treatment of first MM relapse."@en . "DE - Spolkov\u00E1 republika N\u011Bmecko" . "Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma"@en . . . "12"^^ . . "Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma" . .